

2023 #13

April 7, 2023

INSIDE:

A Message from the President of America's Blood Centers.....2
 ADRP Publishes Individual Donor Assessment Toolkit.....3
 Blood Advocacy Week Partners Expanding.....3
 RESEARCH IN BRIEF5
 WORD IN WASHINGTON6
 March Blood Bulletin Published.....7
 Save the Date: ABC Summer Summit & MD Workshop7
 Participate in Day on Capitol Hill7
 PEOPLE8
 MEMBER NEWS.....8
 GLOBAL NEWS8
 COMPANY NEWS9
 CALENDAR.....9
 POSITIONS.....10

Rob Van Tuyle Becomes ABC President & New ABC Board Announced

Rob Van Tuyle has been elected as the president of America's Blood Centers' (ABC) Board of Directors for a two-year term. He succeeds LIFELINE Blood Services' John B. Miller, MBA, who will now assume the role of past president. Mr. Van Tuyle is the executive vice president and chief operations officer of Vitalant, where his responsibilities include blood operations, laboratory and clinical services, and marketing and sales. He previously served as the president of Vitalant's blood services and served as chief financial officer and chief executive officer of BloodSource. Mr. Van Tuyle is a certified public accountant with more than 25 years of experience in executive management. He holds a bachelor's degree in accounting from the University of Santa Clara.



The new slate of officers for the ABC Board of Directors has also been approved and includes:

- LifeSouth Community Blood Centers' Kim Kinsell, JD (Vice President);
- Carter BloodCare's Laurie Sutor, MD, MBA (Secretary/Treasurer); and
- LIFELINE Blood Services' John B. Miller, MBA (Past President).

The other members of the ABC Board of Directors are:

- LifeShare Blood Center's Chad A. Douglas;
- Rock River Valley Blood Center's Lisa Entrikin;
- OneBlood's Martin Grable; and
- New York Blood Center Enterprises' Rick Youngblood.

ABC also announced the chairs of its committees who will also serve two-year terms. They include:

- Communications & National Partnerships – Theresa Pina (Gulf Coast Regional Blood Center);
- Membership – Harpreet Sandhu, MBA (Stanford Blood Center);
- Policy Council – Stacy Sime, MT(ASCP), SBB (LifeServe Blood Center);
- Quality – Jane Miller, MBA, MT(ASCP) (Shepard Community Blood Center);
- Quality Education – Rob Harper, SunCoast Blood Centers;
- Quality Regulatory and HCT/P – Wendell Jones, MT(ASCP)SBB (LifeShare Blood Center);
- SMT – Kip Kuttner, DO (Miller-Keystone Blood Center);
- SMT Journal Club – Nancy Benitez, MHS(ASCP)SBB (OneBlood); and
- SMT *Blood Bulletin* – Daniela Hermelin, MD (ImpactLife). ♦

A Message from the President of America's Blood Centers

Change is inevitable. As my term as president of America's Blood Centers (ABC) begins, I am reminded of how much change has taken place over the past three-plus years. Community blood centers, this association, and the blood community have navigated the disruption of the COVID-19 pandemic. Our dedication and commitment to ensuring that a safe and robust blood supply remained available for all patients in need never wavered, thanks to our ability to work collaboratively as we pivoted operations.

The collaborative and collegial spirit of ABC members and the resiliency of the blood community remains in the wake of the pandemic as we discuss solutions and share best practices. This includes implementing evolving donor deferral policies and addressing supply chain and workforce shortages while ensuring the availability of blood whenever and wherever it is needed. All community blood centers play an integral role together with the ABC Board of Directors, leadership, and staff, collaborating to ensure all voices are heard by our government partners as national health policy is developed.

Advocacy is and always will be the core of ABC. The development of the [2023-26 ABC Strategic Plan](#) has been a collaborative effort between the ABC Board of Directors, leadership, staff — and most importantly — you, the members. Your input made this new plan possible. To ensure the mission and work of the association stays aligned with the needs of all member blood centers, I welcome open discourse with myself, the other members of the board, and the leadership at ABC. This plan is not static and is designed to be flexible as the needs of members shift. In the spirit of collaboration and transparency, the association will continue to provide updates and timely communication regarding the progress towards ABC's strategic goals, while providing opportunities for member feedback.

ABC will also continue to prioritize and advocate for member blood centers through its [2023 Advocacy Agenda](#). I encourage all member blood centers and their staffs to not only familiarize yourself with the legislative and regulatory positions of the association, but to take advantage of the unique opportunity to participate in [Blood Advocacy Week](#) (April 24th-28th) and [2023 Day on Capitol Hill](#). These events are virtual and provide a unique opportunity to connect with external stakeholders to make them aware of the work of community blood centers, while advancing, championing, and amplifying the advocacy efforts of ABC on behalf of member blood centers as you build relationships locally and nationally.

Finally, I would be remiss if I did not thank my predecessor, John B. Miller, MBA, for his leadership over the past two years. I would also like to thank the ABC Board of Directors, the staff at ABC, and you, the member blood centers, for this opportunity to serve as president on your behalf. Collectively, we are committed to being the nimble, innovative voice of member blood centers as we advocate in a collaborative, collegial, and transparent manner to continue bringing value to each of you. Thank you for your support and all that you do on behalf of ABC and the nation's blood supply. 💧

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2023 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers

Chief Executive Officer: Kate Fry
Chief Medical Officer: Jed Gorlin
Editor: Mack Benton
Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: \$390

Send subscription queries to
memberservices@americasblood.org
America's Blood Centers
1717 K St. NW, Suite 900, Washington, DC 20006
Phone: (202) 393-5725
Send news tips to newsletter@americasblood.org.



ADRP Publishes Individual Donor Assessment Toolkit



ADRP, an international division of America's Blood Centers, has created resources to assist with the U.S. Food and Drug Administration's (FDA) proposed shift an individual donor assess,emt. The [toolkit](#) includes:

- social media graphics and messaging;
- a timeline on the history of the proposed change;
- video of the collaboration between blood and LGBTQ+ community stakeholders;
- data from the Human Rights Caampaign Foundation report on the potential impact of the FDA's proposed deferral change; and
- GLAAD's State of HIV Stigma Report.

The full toolkit is available on the [ADRP website](#). 💧

Blood Advocacy Week Partners Expanding

America's Blood Centers (ABC) issued a [news release](#) this week announcing the inaugural [Blood Advocacy Week](#) to promote the value of blood to patients, communities, and the nation's healthcare system. Taking place April 24th-28th, each day of this week will use a virtual event and social media campaigns to highlight a edifferent advocacy priority and provide information about changes that could be made to strengthen and diversity America's blood supply.

Fifty diverse [partners](#) have already signed on to help promote the value of blood through taking part this initiative. This includes the Centers for Disease Control and Prevention, ADRP, Blood Centers of America, American Society for Clinical Pathology, Civil Air Patrol, the Crescent Foundation, Elks, Fresenius Kabi, Georgia Health Policy Center, GLAAD, Health Professions Week, HOSA Future Health Professionals, Johnson & Johnson, the National Hemophilia Foundation, the Northern Arundel Alumnae Chapter of Delta Sigma Theta Sorority, Inc., Operation Pulse Lift, Sickle Cell Foundation of Minnesota, the Student Leadership Council, Terumo Blood and Cell Technologies, Thalassemia International Federation, the Thrive with Pyruvate Kinase Deficiency Organization, University Blood Initiative, and Whitman-Walker Health.

They are being joined by community blood centers across the country, including Blood Assurance, Blood Center of Northcentral Wisconsin, Carter BloodCare, Central California Blood Center, Community Blood Center (Appleton), The Community Blood Center (Appleton, Wis.) Community Blood Center (Dayton, Ohio), the Blood Center (New Orleans), Gulf Coast Regional Blood Center, Houchin Community Blood Bank, ImpactLife LIFELINE Blood Services, LifeServe Blood Center, LifeSouth Community Blood Centers, MEDIC Regional Blood Center, Miller-Keystone Blood Center, Rock River Valley Blood Center, San Diego Blood Bank, Shepard Community Blood Center, Stanford Blood Center, South Texas Blood & Tissue, The Blood Connection, Versiti, and Vitalant.

A full list of partners is available on the Blood Advocacy Week website's [partners](#) page and ABC encourages all organizations to to [become](#) a partner in this important work.

ABC also thanks Fresenius Kabi for being a Blood Advocacy Week sponsor. Additional sponsorship opportunities are [available](#).

(continued on page 4)



Blood Advocacy Week Partners (continued from page 3)

Virtual events taking place during Blood Advocacy Week include the following:

- Monday, April 24th will be dedicated to discussing the current [status](#) of the nation's blood supply and trends impacting the collection and utilization of blood. Registration for the day's virtual event is [now open](#).
- Tuesday, April 25th will be dedicated to promoting the awareness of FDA donor [eligibility](#) changes impacting veterans and gay and bisexual men. Registration for the day's virtual event is [now open](#).
- Wednesday, April 26th will be ABC's virtual Day on Capitol Hill. [Registration](#) is now open.
- Thursday, April 27th will be dedicated to examining changes that will expand early and increased access to blood, including in [pre-hospital](#) and [hospice](#) settings. Registration for the day's virtual event is [now open](#).
- Friday, April 28th will be dedicated to highlighting why increased [diversity](#) – racial, ethnic, and age – is important to patient care. Registration for the day's virtual event is [now open](#).

Additional updates will be provided as they become available. If you or your organization is interested in becoming an official [advocacy partner](#) or [sponsor](#), please contact [Jeff Gohringer](#), director of Strategic Communications and National Partnerships at ABC.

(Source: Blood Advocacy Week [News Release](#), 4/5/23). 💧

Upcoming ABC Webinars – Don't Miss Out!

- **ABC Blood Advocacy Week 2023** – April 24-28. [Registration](#) for events each day of the week as well as [ABC's Day on Capitol Hill](#) (members-only) is open and the initial list of partners is now [available](#). More information available [here](#).
- **Héma-Québec's Perspective – Implementation Experience with Individual Donor Assessment** – May 17 from 3-4 PM EDT. More information coming soon.



BLOOD ADVOCACY WEEK **2023**
APRIL 24-28
BUILDING A STRONGER BLOOD SUPPLY TOGETHER





RESEARCH IN BRIEF

A Summary of the 2022 State of the Science in Transfusion Medicine Symposium. A summary of “The State of the Science” (SoS) symposium hosted by the National Heart, Lung, and Blood Institute (NHLBI), the National Institutes of Health (NIH), the Office of the Assistant Secretary for Health (OASH), and the Department of Health and Human Services (HHS) was published in [Transfusion](#). The paper explains that “[t]he planning committee identified six topic areas.” The first topic was “Blood Donors and the Supply.” According to the authors, “[f]urther investigation is needed to understand the experience of temporarily deferred donors and how to overcome the deferral experience to support decisions to donate in the future.” They also noted that “[a]ssessments should evaluate the impact of various delivery channels to donors in diverse subpopulations and communities.” Topic 2 focused on “Optimizing Transfusion Outcomes for Recipients” The paper stated that “[c]linical, preclinical, and translational studies are required to define: transfusion decision making approaches to chronic transfusion; risk factors that influence red blood cell alloimmunization and iron overload.” Additionally, the authors explained how “[c]linical trials are needed which compare blood products, antifibrinolytics, and coagulation factor concentrates simultaneously.” Topic 3 in the paper delved into “Emerging Infections” as the authors explained that “[d]etermining transfusion risk requires epidemiological assessments, characterization of infection profiles in donors, studies of transfusion transmissibility, and weighing potential interventions guided by risk–benefit, cost-utility, and operational feasibility assessments.” Additionally, that added that “[e]stablishing health policy evaluation frameworks to support pathogen reduction (PR) as a replacement for testing is central to advancing the use of PR.” The fourth topic of paper was “Mechanistic Aspects of Components and Transfusion.” According to the paper, “[n]ovel products, such as *ex vivo* generated blood cells, drug encapsulation in blood cells, artificial blood, and novel uses for current blood products are emerging areas of therapeutic investigation...[R]isks and benefits of all products against one another should be prioritized.” Topic five in the paper explored “New Methods in Transfusion Science.” The authors explained that “[i]nformation and communication technologies, new technologies such as virtual or augmented reality and social media can help us better understand blood donor behavior and facilitate donor recruitment and retention.” They also stated that “[w]ith large-scale computational power and connected, interoperable healthcare data pipelines, there is the promise of data driven in-silico scientific insights stemming from use of artificial intelligence and machine learning in transfusion medicine research.” The final topic, “Donor and Blood Recipient Health Disparities” described how “[r]esearch should focus on the comparison of state level programs for treatment of sickle cell disease and other hemoglobinopathies with an emphasis on costs, reimbursement, and morbidity and mortality data.” The authors concluded that “this report serves to highlight major gaps in our current knowledge and to provide a road map for transfusion medicine research.”

Citation: Custer B., Bloch, E.M., Bryant, B.J., D’Alessandro, A., Delaney, M., Goel, R., Hod, E.A., Josephson, C.D., Katz, L.M., Miller, Y.M., Sayers, M.H., Seheult, J.N., Triulzi, D.J., Berger, J., Zou, S., Hailu, B., Glynn, S.A., Roubinian, N.H. [Proceedings of the 2022 NHLBI and OASH state of the science in transfusion medicine symposium](#). *Transfusion*. 2023

Contributed by Richard Gammon, MD, Medical Director at OneBlood 💧





WORD IN WASHINGTON

The U. S. Department of Health and Human Services (HHS) published a [notice](#) in the *Federal Register* on April 5th soliciting nominations for the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA). According to the notice, the agency is seeking “qualified candidates to five public member positions on the ACBTSA. The ACBTSA is a federal advisory committee within HHS. Qualified individuals will be nominated to the Secretary of HHS for consideration of appointment as members of the ACBTSA. Members are invited to serve on the [advisory] committee for up to four-year terms. The committee was established to provide advice to the Secretary on a range of policy issues related to blood, blood products, and tissues. The functions of the committee are solely advisory in nature.” Nominations should include a curriculum vitae or resume and a personal statement (no more than 300 words) and are due by May 5th and should be submitted via [email](#).

(Source: *Federal Register* [Notice](#), 4/5/23)

The Verifying Accurate Leading-edge IVCT Development (VALID) Act has been reintroduced in the Senate. The proposed legislation would potentially change the way lab developed tests are regulated. ABC has previously expressed concern with the complexity and potential burden on blood centers that the VALID Act would establish and has worked with congressional committees of jurisdiction to ensure they are aware of its potential impact on community blood centers. ABC anticipates Congress will continue to engage on this subject, requiring ongoing advocacy efforts, as the U.S. Food and Drug Administration has indicated the VALID Act is a priority. Updates will be provided to member blood centers as they become available. Please contact ABC Senior Director of Federal Government Affairs [Diane Calmus, JD](#) with questions.

The U.S. Food and Drug Administration (FDA) published a revised draft guidance on April 5th titled “Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act Guidance for Industry.” The draft guidance “recommends that applicants and manufacturers provide additional details and follow additional procedures to ensure FDA has the specific information it needs to help prevent or mitigate shortages.” It also states that “manufacturers should notify the Agency before a meaningful disruption in their own supply of a covered finished product occurs. For example, [the] FDA should not first learn of a meaningful supply disruption resulting from an interruption in manufacturing when a manufacturer is unable to fill an order. Note that after providing the initial notification of an interruption in manufacturing of a covered finished product under section 506C of the FD&C Act, FDA recommends that manufacturers provide updates approximately every 2 weeks on the situation, including the expected timeline for resuming normal operations, even if the status remains unchanged.” Additionally, the guidance recommends that “[i]f a manufacturer is unsure of whether to notify FDA of an interruption in manufacturing because the firm does not know whether it is likely to lead to a meaningful disruption in its supply, FDA urges the manufacturer to submit a notification anyway.” The notifications in the guidance are “triggered by a permanent discontinuance or an interruption in manufacturing that is likely to lead to a meaningful disruption in supply of certain finished drugs or biological products or API for those products. However, FDA requests that manufacturers also notify the Agency when they are unable to meet demand for covered finished products, even in the absence of an interruption in manufacturing, for example, when there is a sudden, unexpected spike in demand.”

(Source: FDA [Guidance](#), 4/5/23) 💧



America's Blood Centers®
It's About *Life*.

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.

March Blood Bulletin Published

America's Blood Centers (ABC) has published the [March 2023](#) edition of the [Blood Bulletin](#). The issue, titled "Directed Donations and COVID-19 mRNA Vaccinated Blood Donors," was written by Daniela Hermelin, MD, Chief Medical Officer at ImpactLife; Louis Katz, MD, Chief Medical Officer Emeritus at ImpactLife; Nancy Van Buren, MD, Medical Director at Innovative Blood Resources and Community Blood Center of Kansas City, divisions of New York Blood Center; Kip Kuttner, DO, Vice President and Medical Director at Miller-Keystone Blood Center; Richard Gammon, MD, Medical Director at OneBlood; Debra Smith, MD, PhD, Medical Director at Carter BloodCare; and Kirsten Alcorn, MD, Co-Chief Medical Officer at Bloodworks Northwest. Contributors included: Rita Reik, MD, FCAP, Chief Medical Officer at OneBlood; Claudia S. Cohn, MD, PhD, Professor of Laboratory Medicine and Pathology at the University of Minnesota; and Theresa Nester, MD, Co-Chief Medical Officer at Bloodworks Northwest. [Blood Bulletin](#) is a quarterly publication reviewed and edited by ABC's Scientific, Medical, and Technical (SMT) Publications Committee.

(Source: [MCN 23-032](#), 3/30/23)

Save the Date: ABC Summer Summit & MD Workshop

Mark your calendars for America's Blood Centers (ABC) [Summer Summit and Medical Directors Workshop](#) in St. Louis, Mo. The meeting will take place August 1st-3rd. Hotel [reservations](#) can be made now through the ABC block at Live! by Loews (St. Louis). Attendees will hear updates on blood center operational, scientific, and medical issues, case studies, engaging discussions, and have networking opportunities to connect with peers and colleagues. Additional details, including registration information and a preliminary agenda, are coming soon.

Participate in Day on Capitol Hill

ABC encourages all member blood centers to register for the [2023 Day on Capitol Hill \(Virtual\)](#) on April 26th. This virtual day provides an opportunity for member blood centers to connect with members of Congress and their staffs to discuss the ongoing work at the blood center and the work done collectively by ABC and community blood centers to advance the [ABC Advocacy Agenda](#). This event is a chance for individuals to let their voice be heard as ABC will arrange the virtual meetings for member blood centers with their members of Congress and provide additional resources to help inform them and their staff about the latest policies impacting the blood community. Take advantage of this opportunity to easily meet with your local Congressional leaders and build relationships.

Each person from the blood center who would like to participate in the Day on Capitol Hill must register individually. ABC will arrange for group meetings but will need information for each person in attendance. Please direct any questions to ABC Senior Director of Federal Government Affairs [Diane Calmus, JD](#).

(Source: [MCN 23-020](#), 2/24/23) ♦



PEOPLE

Nick Leibold, MBA has been named chief financial officer (CFO) and executive doctor of business administration at Hoxworth Blood Center. According to a blood center announcement, he joins Hoxworth following a “financial career in highly prestigious investment, financial and pharmaceutical corporations in New York and work as a successful CFO and co-chief executive officer of a pharmaceutical company with employees and operations across 40+ states.” Mr. Leibold has a B.S. in Finance from Miami University and received his MBA from the Stern School of Business at New York University. “Mr. Leibold’s expertise will help us support and strengthen the services we provide to patients and donors in the Tri-State,” said Hoxworth Director José Cancelas, MD, PhD in a blood center announcement. “He brings many attributes to the senior leadership of Hoxworth and will play a key role in our strategic efforts going forward.”

(Source: Hoxworth Blood Center [Announcement](#), 3/27/23) 💧

MEMBER NEWS

The University of Texas MD Anderson Cancer Center (Houston, Texas) and **the University of California Irvine (UCI) Health Blood Donor Center** (Orange, Calif.) have officially joined America’s Blood Centers (ABC). Both organizations have been approved for hospital-based blood center associate membership. Contact [member services](#) for additional information about ABC’s hospital-associate membership. 💧

GLOBAL NEWS

The World Health Organization (WHO) [called](#) attention to the spread of mosquito-borne diseases this week to “northern countries.” According to a report by *Bloomberg*, the WHO stated that “northern countries are at risk of outbreaks of dengue, Zika and chikungunya as climate change increases the range of the mosquitoes that carry these illnesses.” The news organization attributed comments to WHO Global Program Head of Control of Neglected Tropical Diseases that stated, “[c]limate change has played a key role in facilitating the spread of the mosquitoes down south. And then when people travel, naturally the virus goes along with them.” Diana Rojas Alvarez, co-lead of the WHO’s global arbovirus initiative, stated in the report from *Bloomberg* “[mosquitoes] spreading by altitude and by latitude. There are cases reported now in the south of Europe...If the population is susceptible then there is a risk to have large epidemics in these regions.”

(Source: *Bloomberg*, [Europe at risk of dengue and zika summer outbreaks, WHO says](#), 4/5/23)



Photo courtesy of *The Times of Israel*.

A pilot [program](#) to transport blood products via drones is underway in Israel. According to a report from *The Times of Israel*, the first flight took place on April 2nd and included “[u]nits of blood provided by Magen David Adom [that] were flown by [a drone] built by the Brazilian company Speedbird Aero from Rambam Medical Center in Haifa to Galilee Medical Center in Nahariya, 25 kilometers (15 miles) away. The test involved the transfer of 3.8 kilograms (8.4 lbs) of blood. This drone model can carry up to 10 kilograms.”

(Source: *The Times of Israel*, [Israel test-drives drone blood transfers between hospitals](#), 4/2/23) 💧

COMPANY NEWS

Vertex Pharmaceuticals Inc. and **CRISPR Therapeutics** recently finished the [submission](#) of its “rolling biologics license applications (BLAs) to the U.S. Food and Drug Administration for its investigational gene therapy to treat sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). In the news release, the companies explained that priority review has been requested for the BLAs, which “shorten the FDA’s review of the application to eight months from the time of submission versus a standard review timeline of 12 months.” Data supporting the BLAs include “results from the ongoing phase III studies, CLIMB-111 and CLIMB-121, as well as an ongoing long-term follow-up study, CLIMB-131.”

(Source: Vertex Pharmaceuticals Inc. and CRISPR Therapeutics [News Release](#), 4/3/23)

CSL [announced](#) that the European Commission has “granted conditional marketing authorization (CMA)” for its gene therapy to treat severe and moderately severe hemophilia in adults. The one-time treatment is the first hemophilia B gene therapy to be approved in the European Union and European Economic Area. According to the CSL news release, the European Commission based the approval decision on HOPE-B clinical trial data that “showed that hemophilia B patients treated with HEMGENIX® demonstrated stable and durable increases in mean Factor IX activity levels (with a mean Factor IX activity of 36.9 percent) which led to an adjusted annualized bleed rate (ABR) reduction of 64 percent...The HOPE-B study 24-month analysis continued to show a sustained and durable effect of HEMGENIX®. In a clinical setting, the treatment is generally well-tolerated with no serious treatment-related adverse events.” Results from the clinical trial have been [published](#) in the *New England Journal of Medicine*. The data showed “the ABR of spontaneous bleeding episodes and all joint bleeding episodes decreased by 71 percent (95 percent CI: 0.12, 0.71) and 78 percent (95 percent CI: 0.10, 0.46), respectively, from lead-in period to post-treatment. Further, the authors found 96.3 percent of patients discontinued factor IX prophylaxis from day 21 through month 18 post-treatment (the discontinuation rate in the approved U.S. HEMGENIX® product label is 94 percent). Annualized factor IX infusions also significantly decreased from 72.5 infusions per participant during lead-in period (95 percent CI: 63.6, 82.7) to 2.5 infusions (95 percent CI: 0.92, 6.96) post-treatment.”

(Source: CSL News Releases, [2/20/23](#); [2/23/23](#)) 💧

CALENDAR

***Note to subscribers:** Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)*

2023

April 12-13. **Centers for Disease Control and Prevention (CDC) Clinical Laboratory Improvement Advisory Committee Meeting (Virtual)**. More information available [here](#).

April 20. **End of Selection Criteria Based on Sexual Orientation – International Symposium on Alternatives to Donation Deferral (Virtual)**. [Registration](#) is open. More information available [here](#).

April 24-28. **ABC Blood Advocacy Week (Virtual)**. More information available [here](#).

April 25. **U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products (OTP) Town Hall: Gene Therapy Chemistry, Manufacturing, and Controls – April 2023 (Virtual)**. [Registration](#) is open. More information available [here](#).

April 26. **ABC Day on Capitol Hill (Virtual)**. [Registration](#) is open. More information available [here](#).

April 26. **FDA Blood Products Advisory Committee (BPAC) Meeting (Virtual)**. More information available [here](#).

(continued on page 10)

CALENDAR (continued from page 9)

April 27. **FDA's CBER Office of Tissues and Advanced Therapies (OTAT) Public Listening Meeting: Methods and Approaches for Capturing Post-Approval Safety and Efficacy Data on Cell and Gene Therapy Products (Virtual).** [Registration](#) is open. More information available [here](#).

May 4. **The National Biodefense Science Board, managed and operated by the Administration for Strategic Preparedness and Response, Public Meeting (Virtual).** [Registration](#) is open. More information available [here](#).

May 9-11. **2023 ADRP Conference, Charlotte, N.C.** [Registration](#) is open. Additional information is available [here](#).

May 10-11. **29th IPFA/ Paul-Ehrlich-Institut[e] (PEI) International Workshop on Surveillance and Screening of Blood-borne Pathogens, Bologna, Italy.** More information available [here](#).

May 17. **Héma-Québec's Perspective – Implementation Experience with Individual Donor Assessment.** More information coming soon.

Aug. 1-3. **ABC Medical Directors Workshop and Summer Summit, St. Louis, Mo.** More information available [here](#).

Sept. 17-20. **American Association of Tissue Banks Annual Meeting, National Harbor, Md.** More information available [here](#).

Sept. 20-21. **2023 ADRP Master Class (Virtual).** More information coming soon.

Oct. 9-11. **Advanced Medical Technology Association (AdvaMed) The MedTech Conference, Anaheim, Calif.** More information available [here](#).

Oct. 14-17. **AABB Annual Meeting, Nashville, Tenn.** More information available [here](#). 💧

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Director of Donor Resources. The Northern California Community Blood Bank (NCCBB) seeks an exuberant and outgoing team player with extraordinary people skills to join us as Director of Donor Resources. Located in the heart of the magnificent coastal redwoods of Northern California, NCCBB offers the opportunity to be part of an organization with a vibrant community relationship and a mission that can be personally gratifying and meaningful. The Director of Donor Resources is responsible for the development and direction of programs related to recruitment and retention of blood donors in Humboldt and Del Norte Counties. The Director oversees all recruitment efforts, ensuring that they reach collection targets and are in accordance with regulatory standards. Recruitment efforts include mobile and in-house blood drives, community outreach and education, marketing, and publicity. The Director oversees programs for telephone, text, and email donor recruitment. For detail and to apply, visit www.nccbb.net/employment.html.

Enterprise Medical Director. This position is part of an enterprise-wide Chief Medical Office. This role is responsible for providing medical directorship, administrative, technical, and clinical operations of the assigned hospitals, systems, program, and services as well as support medical directorship of New York Blood Center (NYBC) or the greater NYBC enterprise. This position supports management in making information medical decisions, develops and reviews medical oversight and responsibility for the technical and medical policies, processes, and procedures of specific operations. New York Blood Center Enterprises (NYBCe) is one of the largest community-based, non-profit blood collection and distribution organizations in the United States. We proudly serve as a vital community lifeline dedicated to serving patients and advancing global public health. Our four-part mission is to provide high quality blood products, therapeutic apheresis, cord, and stem cell

(continued on page 11)

POSITIONS (continued from page 10)

services, conduct innovative research, develop new products and technologies, and train the next generation of industry leaders. We serve more than 600 hospitals through our six east coast and mid-west divisions and work with dozens of research organizations, academic institutions, and biopharmaceutical companies through our five research enterprises. Click here to view the full job description and apply: [Enterprise Medical Director in New York, New York](#)

Transfusion Lab Supervisor. Join Florida's leading blood bank, OneBlood, as a Lab Supervisor, working 2nd shift, in Lakeland, FL. Bring your leadership, technical expertise, and management experience to support the transfusion testing procedures on patient and/or donor samples. Qualified candidates should possess three (3) or more years' experience in a clinical laboratory, preferably blood banking environment, including one (1) or more years' experience in supervision and management experience, as well as a valid and current Florida Clinical Laboratory Technologist license in Immunohematology or Blood Banking; Supervisor license strongly preferred. To apply and view a complete Job Description of this position, visit www.oneblood.org/careers. OneBlood, Inc. is an Equal Opportunity Employer/Vet/Disability. 💧